Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.32 |
| ▸ | NPC1 | O15118 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 5/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | MITF | O75030 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 4/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21521214 | 1.00 | MAPT (0.32) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL26125473 | 0.87 | — | — | |
| SCHEMBL26125475 | 0.87 | — | — | |
| SCHEMBL21522415 | 0.87 | KAT2B (0.40) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL21522414 | 0.87 | KAT2B (0.40) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL29088961 | 0.86 | NPC1 (0.34) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL26914899 | 0.85 | NPC1 (0.33) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL26914895 | 0.85 | NPC1 (0.33) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL29841952 | 0.84 | TIPARP (0.31) | MAPTNPC1ALDH1A1RAB9AS1PR4 | |
| SCHEMBL21521144 | 0.84 | TIPARP (0.33) | F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-116724044-A | Tri-heterocyclic compound, preparation method and application thereof | 上海湃隆生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022242750-A1 | PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-11-24 | — | — | WO | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112424188-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | MAPT 1388/4885NPC1 2560/4885ALDH1A1 647/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | MAPT 4774/4885NPC1 1967/4885ALDH1A1 1500/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MAPT 3364/4885NPC1 4551/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.